Peter W. T. Pisters
University of Texas MD Anderson Cancer Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Peter W. T. Pisters.
Cancer | 2003
Gunar K. Zagars; Matthew T. Ballo; Peter W. T. Pisters; Raphael E. Pollock; Shreyaskumar R. Patel; Robert S. Benjamin; Harry L. Evans
Prognostic factors for patients with soft‐tissue sarcoma who are treated with conservative surgery and radiation are documented poorly.
Cancer | 2000
Arthur W. Chaney; Alan Pollack; Marsha D. McNeese; Gunar K. Zagars; Peter W. T. Pisters; Raphael E. Pollock; Kelly K. Hunt
Cystosarcoma phyllodes is a rare sarcoma of the breast. Although surgical removal is the mainstay of treatment, the extent of surgery required (excision vs. mastectomy) and the need for additional local therapy, such as radiotherapy, are unclear. The current study evaluated the rate of local and distant failure, as well as potential prognostic factors, to better define appropriate treatment strategies.
Cancer | 2002
Jaffer A. Ajani; R N Jackie Baker; Peter W. T. Pisters; Linus Ho; Paul F. Mansfield; Barry W. Feig; Chusilp Charnsangavej
This Phase II study assessed the response rate and toxicity profile of the combination CPT‐11 and cisplatin administered weekly to patients with untreated, advanced adenocarcinoma of the stomach or the gastroesophageal junction.
Cancer | 2003
Gunar K. Zagars; Matthew T. Ballo; Peter W. T. Pisters; Raphael E. Pollock; Shreyaskumar R. Patel; Robert S. Benjamin
Patients with localized soft tissue sarcoma (STS) who present to specialist centers after undergoing apparent macroscopic total resection often have a significant incidence of residual tumor and may benefit from reresection of the tumor bed. The potential benefits of such reresection have not been documented adequately.
Cancer | 2001
Jaffer A. Ajani; Ritsuko Komaki; Joe B. Putnam; Garrett Walsh; Jon Nesbitt; Peter W. T. Pisters; Patrick M. Lynch; Ara Vaporciyan; Roy Smythe; Sandeep Lahoti; Issac Raijman; Stephen Swisher; D R N Faye Martin; Jack A. Roth
Patients with locoregional carcinoma of the esophagus or gastroesophageal junction have a poor survival rate after surgery. Preoperative chemotherapy or chemoradiotherapy has not improved the outcome for these patients. Our study was designed to assess the feasibility of preoperative induction combination chemotherapy in addition to chemoradiotherapy to improve the curative resection rate, local control, and survival.
Cancer | 2002
Funda Meric; Kenneth R. Hess; Datla G. K. Varma; Kelly K. Hunt; Peter W. T. Pisters; Kresimira M. Milas; Shreyaskumar R. Patel; Robert S. Benjamin; Carl Plager; Nicholas E. Papadopoulos; Michael A. Burgess; Raphael E. Pollock; Barry W. Feig
Downstaging of large soft tissue sarcomas can be accomplished by the use of neoadjuvant chemotherapy (NeoCT). The authors tested the hypothesis that radiographic response to NeoCT predicts improved local control and survival.
Cancer | 1999
David B. Pearlstone; Peter W. T. Pisters; Richard J. Bold; Barry W. Feig; Kelly K. Hunt; Alan W. Yasko; Shreyaskumar Patel; Alan Pollack; Robert S. Benjamin; Raphael E. Pollock
Liposarcoma is one of the most common histologic types of soft tissue sarcoma and presents a wide spectrum of clinical behavior. The authors examined the correlation among histologic subtypes, outcomes, and patterns of recurrence among patients with extremity liposarcomas.
Cancer | 2002
Patrick P. Lin; Volkan B. Guzel; Peter W. T. Pisters; Gunar K. Zagars; Kristin L. Weber; Barry W. Feig; Raphael E. Pollock; Alan W. Yasko
Soft tissue sarcomas of the hand and foot present unique management challenges. The purpose of the current study study was to determine oncologic outcome, particularly with respect to factors affecting local recurrence, distant recurrence, and disease‐specific survival.
Cancer | 2001
Jason B. Fleming; Scott B. Cantor; Datla G. K. Varma; Daniel Holst; Barry W. Feig; Kelly K. Hunt; Shreyaskumar R. Patel; Robert S. Benjamin; Raphael E. Pollock; Peter W. T. Pisters
National Cancer Center Network (NCCN) and Society of Surgical Oncology (SSO) practice guidelines recommend chest computed tomography (CT) as part of the staging evaluation of patients with extremity soft tissue sarcoma (STS). In the current study, the authors evaluated the use and yield of chest roentgenography (CXR) and selective chest CT to screen for pulmonary metastases in patients with T1 STS.
Cancer | 2002
Geoffrey A. Porter; Scott B. Cantor; Syed A. Ahmad; Jeffrey T. Lenert; Matthew T. Ballo; Kelly K. Hunt; Barry W. Feig; Shreyaskumar R. Patel; Robert S. Benjamin; Raphael E. Pollock; Peter W. T. Pisters
Published practice guidelines recommend routine chest computed tomography (CT) scanning as part of the staging evaluation for patients with T2 soft tissue sarcomas (STS), although there is no direct evidence to support this practice. The objective of this study was to determine the yield and cost‐effectiveness of routine versus selective chest CT scanning for the staging of patients with T2 STS and to identify any subgroups for whom a more selective approach to chest CT scanning could be considered.